MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 70 filers reported holding MARINUS PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.20 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,269,963 | -29.6% | 2,145,337 | -5.0% | 7.70% | -30.5% |
| Q2 2023 | $24,516,678 | +35.6% | 2,257,521 | -13.8% | 11.08% | +48.8% |
| Q1 2023 | $18,078,662 | -15.8% | 2,620,096 | -38.0% | 7.44% | +143.5% |
| Q4 2022 | $21,480,000 | +13.3% | 4,222,648 | +14.6% | 3.06% | -26.8% |
| Q3 2022 | $18,959,000 | 0.0% | 3,684,622 | 0.0% | 4.18% | +93.6% |
| Q2 2022 | $18,959,000 | -44.1% | 3,684,622 | +1.5% | 2.16% | -72.6% |
| Q1 2022 | $33,936,000 | -21.3% | 3,629,622 | 0.0% | 7.88% | -31.9% |
| Q4 2021 | $43,119,000 | +4.4% | 3,629,622 | 0.0% | 11.56% | +49.3% |
| Q3 2021 | $41,305,000 | -36.6% | 3,629,622 | -0.1% | 7.74% | -31.2% |
| Q2 2021 | $65,152,000 | +16.3% | 3,631,694 | +0.4% | 11.26% | +10.5% |
| Q1 2021 | $56,011,000 | +26.9% | 3,618,334 | 0.0% | 10.19% | +19.9% |
| Q4 2020 | $44,143,000 | +26.4% | 3,618,334 | +33.1% | 8.50% | +11.0% |
| Q3 2020 | $34,930,000 | – | 2,718,334 | – | 7.66% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 3,629,622 | $33,936,000 | 7.88% |
| VR Adviser, LLC | 3,156,803 | $29,516,000 | 4.78% |
| Bleichroeder LP | 1,322,463 | $12,365,000 | 2.19% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $13,380,000 | 1.30% |
| 683 Capital Management, LLC | 1,932,829 | $18,072,000 | 0.97% |
| Granite Point Capital Management, L.P. | 472,056 | $4,414,000 | 0.92% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,766,000 | $25,862,000 | 0.79% |
| Avoro Capital Advisors LLC | 3,150,000 | $29,453,000 | 0.54% |
| Artal Group S.A. | 1,000,000 | $9,350,000 | 0.39% |
| Stonepine Capital Management, LLC | 56,747 | $531,000 | 0.22% |